Surmodics, Inc. (SRDX)
NASDAQ: SRDX · Real-Time Price · USD
27.26
-0.24 (-0.87%)
Oct 24, 2025, 4:00 PM EDT - Market closed
Surmodics Revenue
Surmodics had revenue of $29.57M in the quarter ending June 30, 2025, a decrease of -2.55%. This brings the company's revenue in the last twelve months to $120.80M, down -0.02% year-over-year. In the fiscal year ending September 30, 2024, Surmodics had annual revenue of $126.08M, down -4.91%.
Revenue (ttm)
$120.80M
Revenue Growth
-0.02%
P/S Ratio
3.21
Revenue / Employee
$310,542
Employees
389
Market Cap
389.75M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 126.08M | -6.51M | -4.91% |
| Sep 30, 2023 | 132.58M | 32.63M | 32.65% |
| Sep 30, 2022 | 99.95M | -5.19M | -4.93% |
| Sep 30, 2021 | 105.14M | 10.27M | 10.83% |
| Sep 30, 2020 | 94.86M | -5.21M | -5.21% |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
SRDX News
- 2 months ago - Surmodics Reports Third Quarter of Fiscal Year 2025 Financial Results; Updates Fiscal Year 2025 Financial Guidance - Business Wire
- 2 months ago - Surmodics to Report Third Quarter of Fiscal 2025 Financial Results on August 8 - Business Wire
- 6 months ago - Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance - Business Wire
- 6 months ago - Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30 - Business Wire
- 6 months ago - Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon - Business Wire
- 7 months ago - Surmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries - Business Wire
- 8 months ago - Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR - Business Wire
- 8 months ago - FTC sues to block private equity firm's deal to buy medical device coatings maker Surmodics - Reuters